Not all people with CLL need therapy. Inspite of all current improvements, the iwCLL still endorses watchful observation for clients with asymptomatic ailment.86 This suggestion relies on not less than two randomized trials comparing observation to either chlorambucil monotherapy or fludarabine, cyclophosphamide and rituximab (FCR).103,104 The two